Qyuns Therapeutics' (HKG:2509) phase 3 clinical study of its QX002N injection reached its primary endpoint showing better efficacy, safety, and tolerance in patients with moderate-to-severe active ankylosing spondylitis, a Monday bourse filing said.
The study showed the injection to have much higher efficacy than its market counterparts while its safety study revealed injection's treatment-emergent adverse events in grades 1 and 2.
The drug's incidence of adverse event rating was comparable to that of marketed drugs in the same class, with no new safety signals identified, according to the filing.
QX002N is a high-affinity monoclonal antibody and targets the IL-17A which is a key player in the pathological mechanism of various autoimmune diseases.
The injection is for the treatment of the chronic progressive inflammatory disease of the spinal joints, Ankylosing Spondylitis.
The disease causes inflammation of the spinal joints, resulting in reduced flexibility of the joints and stiffness in the spine over time.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。